229 related articles for article (PubMed ID: 19282758)
1. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
3. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
[TBL] [Abstract][Full Text] [Related]
4. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
5. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Kawauchi A; Nakao M; Miki T
Cancer; 2003 Aug; 98(4):730-6. PubMed ID: 12910516
[TBL] [Abstract][Full Text] [Related]
6. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.
He Q; Mao Y; Wu J; Decker C; Merza M; Wang N; Eriksson S; Castro J; Skog S
Int J Oncol; 2004 Oct; 25(4):945-53. PubMed ID: 15375544
[TBL] [Abstract][Full Text] [Related]
7. High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma.
Takayama T; Mugiya S; Sugiyama T; Aoki T; Furuse H; Liu H; Hirano Y; Kai F; Ushiyama T; Ozono S
Jpn J Clin Oncol; 2006 Sep; 36(9):564-9. PubMed ID: 16861722
[TBL] [Abstract][Full Text] [Related]
8. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
Kaya K; Ayan S; Gokce G; Kilicarslan H; Yildiz E; Gultekin EY
Scand J Urol Nephrol; 2005; 39(1):25-9. PubMed ID: 15764267
[TBL] [Abstract][Full Text] [Related]
9. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Jung K
Cancer Sci; 2008 Jun; 99(6):1188-94. PubMed ID: 18422740
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma.
Ohno Y; Izumi M; Yoshioka K; Ohori M; Yonou H; Tachibana M
Oncol Rep; 2008 Sep; 20(3):511-6. PubMed ID: 18695899
[TBL] [Abstract][Full Text] [Related]
11. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K
Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum-circulating RNA in patients with conventional renal cell cancer.
Feng G; Li G; Gentil-Perret A; Tostain J; Genin C
Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864
[TBL] [Abstract][Full Text] [Related]
13. Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma.
Campbell L; Nuttall R; Griffiths D; Gumbleton M
Cancer; 2009 Aug; 115(15):3457-67. PubMed ID: 19526593
[TBL] [Abstract][Full Text] [Related]
14. Characterization of HLA-G expression in renal cell carcinoma.
Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
[TBL] [Abstract][Full Text] [Related]
15. A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma.
Wu J; Mao Y; He L; Wang N; Wu C; He Q; Skog S
Anticancer Res; 2000; 20(6C):4815-20. PubMed ID: 11205225
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Stenzl A; Beger G; Rinnab L; Kuczyk MA; Kuefer R
Urol Int; 2007; 79(1):41-3. PubMed ID: 17627167
[TBL] [Abstract][Full Text] [Related]
17. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
Jagarlamudi KK; Hansson LO; Eriksson S
BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
[TBL] [Abstract][Full Text] [Related]
18. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
von Euler HP; Ohrvik AB; Eriksson SK
Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
[TBL] [Abstract][Full Text] [Related]
19. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma.
Li Z; Wang Y; Ma J; He J; Zhou J; He E; Skog S
Anticancer Res; 2010 Apr; 30(4):1295-9. PubMed ID: 20530443
[TBL] [Abstract][Full Text] [Related]
20. Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver.
Nisman B; Appelbaum L; Yutkin V; Nechushtan H; Hubert A; Uziely B; Pode D; Peretz T
Anticancer Res; 2016 Apr; 36(4):1791-7. PubMed ID: 27069161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
